GLPwatch

Instrumental Variable Methods to Target Hypothetical Estimands With Longitudinal Repeated Measures Data: Application to the STEP 1 Trial.

Stat Med · 2025

Last updated 2026-05-28

In a 68-week study of 1,961 adults, researchers compared the weight-loss effects of semaglutide (a GLP-1 drug) to a placebo. They used a new method to estimate what the results would have been if all participants had fully followed their treatment plan, finding that semaglutide led to sustained weight loss over time. The method also allowed them to estimate the effect if both groups had fully adhered to their treatments.

AI summary of the abstract below.

JournalStat Med, 2025
Citations3
Molecules
Conditions studied Obesity, Type 2 Diabetes

Abstract

The STEP 1 randomized trial evaluated the effect of taking semaglutide versus placebo on body weight over a 68-week duration. As with any study evaluating an intervention delivered over a sustained period, nonadherence was observed. This was addressed in the original trial analysis within the Estimand Framework by viewing nonadherence as an intercurrent event. The primary analysis applied a treatment policy strategy which viewed it as an aspect of the treatment regimen, and thus made no adjustment for its presence. A supplementary analysis used a hypothetical strategy, targeting an estimand that would have been realized had all participants adhered, under the assumption that no post-baseline variables confounded adherence and change in body weight. In this article, we propose an alternative instrumental variable (IV) method to adjust for nonadherence which does not rely on the same "unconfoundedness" assumption and is less vulnerable to positivity violations (e.g., it can give valid results even under conditions where nonadherence is guaranteed). Unlike many previous IV approaches, it makes full use of the repeatedly measured outcome data, and allows for a time-varying effect of treatment adherence on a participant's weight. We show that it provides a natural vehicle for defining two distinct hypothetical estimands: the treatment effect if all participants would have adhered to semaglutide, and the treatment effect if all participants would have adhered to both semaglutide and placebo. When applied to the STEP 1 study, they suggest a sustained, slowly decaying weight loss effect of semaglutide treatment.

Verbatim abstract via PubMed 40214049 ↗